<DOC>
	<DOCNO>NCT02270944</DOCNO>
	<brief_summary>The purpose present study ass compare healthy non-pregnant woman 18 40 year age safety immunogenicity liquid formulation Group B Streptococcus ( GBS ) Trivalent Vaccine ( require reconstitution prior administration ) , lyophilize formulation GBS Trivalent Vaccine , administer non-pregnant pregnant woman clinical development program date .</brief_summary>
	<brief_title>Safety Immunogenicity Liquid Formulation Group B Streptococcus Trivalent Vaccine Lyophilized Formulation Group B Streptococcus Trivalent Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy female 1840 year age , inclusive . 2 . Individuals give write consent nature study explain accord local regulatory requirement . 3 . Individuals good health determine outcome medical history , physical examination clinical judgment investigator . 4 . Individuals comply study procedure available followup . 1 . Individuals pregnant ( urine pregnancy test Study Day 1 ) anticipate become pregnant prior end study , Day 181 Visit . 2 . Individuals `` childbearing potential '' , heterosexually active , use `` acceptable contraceptive method '' least 2 month prior study entry continue use acceptable contraceptive method end study , Day 181 Visit . Of childbearing potential defined status post onset menarche meeting follow condition : menopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy , status hysterectomy . Acceptable birth control method define one following : hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) ; barrier ( condom spermicide diaphragm spermicide ) every time intercourse ; intrauterine device ( IUD ) ; monogamous relationship vasectomize partner vasectomize least six month prior subject 's study entry ; abstinence/no sexual intercourse . 3 . Individuals nurse ( breastfeed ) . 4 . Individuals participate clinical trial another investigational product 30 day prior first study visit intend participate another trial prior end study , Day 181 Visit . 5 . Individuals previous immunization vaccine contain Group B Streptococcus antigens . 6 . Individuals receive : live vaccine 30 day prior study vaccination inactivate vaccine 15 day prior study vaccination vaccine within 30 day study vaccination exception : inactivated influenza vaccine may administer 7 day prior study vaccination 7 day study vaccination 7 . Individuals fever ( oral temperature ≥ 38°C ) within 3 day prior Study Day 1 . 8 . Individuals acute chronic infection ( ) ( e.g . require systemic antibiotic treatment antiviral therapy ) within 7 day prior Study Day 1 . 9 . Individuals history severe allergic reaction previous vaccination medication anaphylactic shock , asthma , urticaria , allergic reaction hypersensitivity vaccine component . 10 . Individuals know suspected impairment immune system include know suspected HIV infection HIVrelated disease , history active autoimmune disorder receipt immunosuppressive therapy . 11 . Long term use glucocorticoid , include oral parenteral prednisone ≥ 20 mg/day equivalent 2 consecutive week ( 2 week total ) within 30 day prior enrollment . Use inhale , intranasal , intraarticular , topical corticosteroid allow . 12 . Individuals receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation past 12 week . 13 . Individuals progressive severe neurologic disorder , seizure disorder , epilepsy GuillainBarré syndrome . 14 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . 15 . Individuals able comprehend follow require study procedure whole period study . 16 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Group B Strep</keyword>
	<keyword>GBS</keyword>
	<keyword>vaccine comparability</keyword>
</DOC>